Abstract
Purpose To assess the efficacy, safety, and predictability of the Visian Implantable Collamer Lens (ICL) model having a central port in patients over 40 years of age. Methods This study included 33 eyes from 21 patients who underwent V4c ICL implantation for the correction of myopia and myopic astigmatism. We assessed uncorrected (UDVA) and corrected (CDVA) distance visual acuity, refraction, intraocular pressure (IOP), endothelial cell density (ECD), vault, and adverse events occurring over a 1-year period. Results Mean age of the patients at the time of implantation was 43.52 ± 4.49 years (range: 40 to 56 years). Efficacy and safety indexes were 1 and 1.09, respectively. Surgical outcomes for CDVA were as follows: no eye lost any lines, 19 eyes (57.58%) showed no CDVA changes, 7 eyes (21.21%) gained 1 line, 4 eyes (12.12%) gained 2 lines, and 3 eyes (9.09%) gained ≥3 lines. Mean postoperative spherical equivalent (SE) was −0.09 ± 0.47 D. A total of 29 eyes (87.8%) were within ±0.50 D and 31 eyes (93.9%) were within ±1.00 D of the desired SE. At 1-year, mean IOP was 15.27 ± 3.03 mmHg (range: 9 to 20 mmHg, p=0.12 pre vs. post) and mean ECD was 2516 ± 234 cells/mm2 (p=0.29 pre vs. post). Mean postoperative vault was 320 ± 136 μm, with 201–300 μm being the most prevalent vault range for 9 eyes (31.03%). None of the eyes showed a vault >701 μm. There were neither intraoperative nor postoperative complications; in fact, all ICL implantation procedures were uneventful. Conclusions Our study's findings support the use of this lens in patients over 40 years of age. A long follow-up period is advisable to monitor ICL position relative to the crystalline lens.
Highlights
To assess the efficacy, safety, and predictability of the Visian Implantable Collamer Lens (ICL) model having a central port in patients over 40 years of age
A total of 33 eyes from 21 patients (6 males and 15 females) aged 40 to 56 were consecutively recruited for this prospective study. ese patients underwent the implantation of the Visian V4c ICL to have their myopia and their myopic astigmatism corrected at the Oftalvist Clinic
E procedures took place between March 2017 and February 2019. e inclusion criteria were age ≥40 years, and myopic and astigmatic refractive error to be corrected with the V4c ICL. e exclusion criteria were endothelial cell density (ECD) below 2000 cell/mm2, anterior chamber depth (ACD) < 2.8 mm, cataract, and a history of glaucoma or retinal detachment, neuro-ophthalmic diseases, macular degeneration, retinopathy, or any inflammatory disease. e study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board
Summary
Safety, and predictability of the Visian Implantable Collamer Lens (ICL) model having a central port in patients over 40 years of age. Recent reviews and meta-analysis have confirmed its safety and effectiveness in moderately and highly myopic eyes throughout short, medium, and long follow-up periods [1, 2] With these outcomes, and bearing in mind that no vision-threatening complications occurred, the use of this IOL is recommended for the correction of a wide range of myopic errors. The objective of this study was to assess the visual and refractive outcomes of the V4c Visian ICL model for the correction of myopia and astigmatism when implanted in patients over 40 years of age
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
